ReviewFrontiers in veterinary science2026
Swine Group A rotavirus vaccines: current status, adjuvant strategies, challenges, and future perspectives.
Review in Frontiers in veterinary science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Swine Group A rotavirus is one of the primary intestinal pathogens causing severe diarrhea in newborn piglets, with high incidence and mortality resulting in substantial economic losses to the global swine industry. Vaccination, alongside rigorous biosecurity measures, remains the core strategy for controlling porcine Group A rotavirus infection; however, continuous genetic variation via genomic reassortment, point mutations, and diverse G/P genotype combinations drives the constant emergence of new circulating strains that may evade immune protection from existing vaccines. These genetic changes may also give rise to highly pathogenic variants, increasing large-scale outbreak risk. Therefore, developing vaccines that provide stable, broad cross-protection against viral strain diversity is particularly critical. Vaccine adjuvants play a vital role in enhancing and modulating immune responses, broadening protection spectra, and reducing the antigen dose required for protection especially valuable when facing rapidly changing genotypes or limited vaccine antigen supplies. In recent years, advances in adjuvant design and formulation strategies have clearly improved the immunogenicity and duration of protection of swine Group A rotavirus vaccines, as evidenced by significantly reduced diarrhea incidence and viral shedding intensity in vaccinated piglets. Building on an overview of the current status, advantages, and challenges of different porcine Group A rotavirus vaccine types, this review focuses on the mechanisms of action, application advantages, existing limitations, and methodological strategies of adjuvants. It further analyzes the potential contribution of adjuvant strategies to developing a universal porcine rotavirus vaccine capable of broad, long-lasting cross-protection. Finally, this review identifies key unresolved scientific questions and critical knowledge gaps in the field, with the aim of guiding future research priorities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.